News

Sydney, Australia – 1st November 2023 AMSL Diabetes announces that as of 1st November 2023, the OneTouch Verio Blood Glucose Meter and Verio Glucose Testing Strips manufactured by LifeScan is no longer available in Australia. This means that the OneTouch Blood Glucose Meter range will no longer be supplied in Australia for new and existing …

Continue reading "OneTouch Verio & Verio Strips by LifeScan Discontinued in Australia"

SYDNEY, Australia – 26 July 2023: Dexcom Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its Australian subsidiary Australasian Medical and Scientific Ltd (AMSL Diabetes) are pleased to announce that Dexcom G6 Continuous Glucose Monitoring (CGM) systems are now compatible with selected Garmin devices* in Australia. Pairing …

Continue reading "Dexcom x Garmin Connectivity Announcement"

SYDNEY, Australia – 1 July 2023: Dexcom Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its Australian subsidiary Australasian Medical and Scientific Ltd (AMSL Diabetes) are excited to share that AMSL Diabetes has been successful in their application to the Department of Veterans’ Affairs (DVA) in providing fully …

Continue reading "Dexcom CGM and Tandem t:slim X2 Insulin Pump products now funded for eligible Department of Veterans’ Affairs (DVA) clients"

SYDNEY, Australia – 1 March 2023: Dexcom Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its Australian subsidiary Australasian Medical and Scientific Ltd (AMSL Diabetes) today announce the official launch of the Dexcom Warrior program in Australia. The Dexcom Warrior Program is a global advocacy community that aims …

Continue reading "Global Dexcom Warriors Program Launches in Australia"

SYDNEY, Australia – 30 January 2023: Dexcom Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its Australian subsidiary Australasian Medical and Scientific Ltd (AMSL Diabetes) have released a School Guide to give schools the information they need to better support students with type 1 diabetes. The Guide aims …

Continue reading "School Guide To Raise Diabetes Awareness in Schools"

SYDNEY, Australia – 10 November 2022: In time for World Diabetes Day, model Bambi Northwood -Blyth joins Dexcom Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, and its Australian subsidiary Australasian Medical and Scientific Ltd (AMSL) Diabetes to announce the arrival of the global Dexcom Warrior program in …

Continue reading "Model Bambi Northwood-Blyth Supports Dexcom Warriors Coming to Australia in 2023"

As of Friday 29th July 2022, AMSL Diabetes will discontinue the sale of Transmitters and Sensors for the Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) system. In addition to removing Dexcom G5 Mobile from the NDSS CGM Subsidy Initiative on 1 March 2022, Dexcom G5 Mobile will no longer be available for private purchase via the …

Continue reading "Dexcom G5 Mobile manufactured by Dexcom – Supply Update"

1 August 2022 Update – Streamlined access for self-funded Existing Dexcom G6 Users has now closed as of 31st July 2022. All individuals, whether existing customers or new to Dexcom G6 will need to see their healthcare professional in order to get started with this application process. 1 July 2022 – Dexcom and AMSL Diabetes …

Continue reading "Government launches subsidised Continuous Glucose Monitoring for all Australians living with type 1 diabetes from 1 July 2022"

21 April 2022 – Dexcom and AMSL Diabetes welcome the recent bi-partisan commitment to providing access to continuous glucose monitoring for all people with Type 1 diabetes in Australia. Expanding the subsidy access to all people with Type 1 diabetes in Australia irrespective of their age and concession card status is an important reform that improves …

Continue reading "Government pledges additional Continuous Glucose Monitoring Subsidies for all Australians living with type 1 diabetes"

April 2022 – AMSL Diabetes is excited to announce the launch of Control-IQ™ technology for the t:slim X2™ insulin pump! The t:slim X2 insulin pump (compatible with Dexcom G6 continuous glucose monitoring) is capable of remote feature updates.* Recently, we welcomed the newest software to launch within Australia; Control-IQ. Control-IQ technology is an advanced hybrid …

Continue reading "Control-IQ Technology for the t:slim X2 Insulin Pump Launches in Australia"

Advanced features not available on any other device Government paves the way for improved access to game-changing technology for eligible Australians living with Type 1 diabetes Sydney, 8 February 2022 – AMSL Diabetes has today announced that the Dexcom G6 Continuous Glucose Monitoring (CGM) system will be available through the Australian Government’s CGM Subsidy Initiative …

Continue reading "National Diabetes Services Scheme (NDSS) fully subsidises the most advanced Dexcom Continuous Glucose Monitoring (CGM) technology"

January 2022 We would like to advise that we have been notified that our delivery couriers are experiencing some delays due to the ongoing COVID-19 crisis. We are continuing to process all orders and thank you for your patience. To help keep our phone lines available for urgent enquiries, if you would like an update …

Continue reading "Courier Shipping Delays may occur due to COVID-19"

Latest Update: November 2021 The app update was initially rolled out in early October for existing Android Dexcom G6 customers. For iOS devices, the update has recently been released in mid-November, 2021. October 2021 We are thrilled to bring you an update to the Dexcom G6 app! Designed to improve the user’s experience, this update …

Continue reading "Dexcom unveils update for Dexcom G6 App with New and Improved Features (Last Updated 23 Nov 2021)"

October 2021 AMSL Diabetes are thrilled to announce a sponsoring partnership with the DANII Foundation. The DANII Foundation passionately advocates for all individuals living with type 1 diabetes, a condition close to their heart, as their goal is to see a world where people living with type 1 diabetes can have access to life-changing technology. …

Continue reading "AMSL Diabetes to sponsor DANII Foundation"

September 2021 Following an update to the Dexcom account creation interface from 9th of September 2021, selected new Dexcom G5 Mobile customers may need to complete an additional step when creating their Dexcom account. This update will not affect existing Dexcom G5 Mobile customers. For further information, please refer to this document. The update introduces …

Continue reading "Update Prompts Additional Step in Setting up Dexcom Account for some New Customers"

August 2021 AMSL Diabetes are thrilled to announce the sponsorship of the Type 1 Foundation. The Type 1 Foundation is a not-for-profit charity raising awareness of type 1 diabetes through education in schools, medical practices, and the wider community. It is a volunteer-based organisation that aims to empower a generation of young people living with …

Continue reading "AMSL Diabetes sponsor not-for-profit organisation; Type 1 Foundation"

August 2021 AMSL Diabetes are delighted to announce the sponsorship of Astra-Lia England who will be participating in the upcoming TV series of “Adventure All Stars”. The international “Adventure All Stars” program is created and produced by Charity TV Global, an award-winning Australian TV production company. They successfully combine entertainment with philanthropy; rewarding people for …

Continue reading "AMSL Diabetes announce sponsorship for Charity TV Global’s “Adventure All Stars” Series"

August 2021 AMSL Diabetes are excited to announce the sponsorship of the Willow Rose Foundation for Diabetes. The Willow Rose Foundation for Diabetes is a not-for-profit organisation that was born out of a passion to see all people living with diabetes thrive. By bringing together the experiences of individuals living with diabetes, they hope to …

Continue reading "AMSL Diabetes pledge support for Willow Rose Foundation for Diabetes"

August 2021 Richard Plowright, Managing Director and Owner of Australasian Medical & Scientific Limited (AMSL) and New Zealand Medical & Scientific (NZMS) has announced his retirement, after over 30 years of providing the Australasian market with access to leading edge healthcare solutions from all over the world. As of the 1st August 2021, Richard has …

Continue reading "Dexcom, Inc. acquires AMSL and NZMS"

7th April 2021 The Therapeutic Goods Administration (TGA) suspension of the ARTG entry for the Tandem Diabetes Care t:slim X2 insulin pump has officially been lifted. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA and have now successfully addressed their concerns for the t:slim X2 insulin pump. For more information …

Continue reading "Tandem t:slim X2 Insulin Pump Suspension Lifted"

29th March 2021 As of 29th March 2021, AMSL Diabetes has discontinued the sale of the t:slim X2 insulin pump with Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) integration. This announcement does not affect the supply of the t:slim X2 insulin pump with Basal-IQ™ technology and any subsequent versions of the pump. Existing customers will …

Continue reading "Tandem t:slim X2 Insulin Pump with Dexcom G5 Mobile Integration Supply Update"

15th January 2021 The Australian Government has updated the NDSS CGM Subsidy Initiative to include the NEW Dexcom G6 Continuous Glucose Monitoring System. As of Monday 18th of January 2021,  if you are using a Tandem t:slim X2 insulin pump and are eligible for the NDSS CGM Subsidy Initiative you can now have access to …

Continue reading "The Australian Government has updated the NDSS CGM Subsidy Initiative"

24th November 2020 Recently the Therapeutic Goods Administration (TGA) expressed concern about the Tandem Diabetes Care t:slim X2 insulin pump. AMSL Diabetes and Tandem Diabetes Care have been in discussions with the TGA to address their concern. However the TGA have informed us of their intent to temporarily suspend the ARTG entry for the t:slim …

Continue reading "Tandem Suspension Notice (Last Updated 1 April 2021)"

Dexcom G4 PLATINUM manufactured by Dexcom has been discontinued for sales directly from AMSL Diabetes.

Basal-IQ technology is now available in Australia!  The t:slim X2 insulin pump with Basal-IQ technology is compatible with the new Dexcom G6 CGM System.

On the 2nd April 2020, Dexcom announced the upcoming obsolescence for Dexcom G4 PLATINUM and Dexcom G5 Mobile at dexcom.com/obsolescence. This specific announcement and timeline is only applicable to residents of the United States.

Important Message from AMSL General Manager, Ian Slater on COVID-19 23rd March 2020 The impact of COVID-19 has been unprecedented as it continues to affect people and organisations around the world. The Federal Government, State Governments and Health Authorities continue to provide detailed guidelines on how to mitigate risks and ensure containment. We encourage all …

Continue reading "Important Update: AMSL’s Commitment during COVID-19"

Sydney, Australia, March 2020 The Dexcom G6 Continuous Glucose Monitoring (CGM) System, has been registered in Australia (ARTG 330535).                                                                 Dexcom G6 represents the latest …

Continue reading "Dexcom G6 CGM System Update"

Sydney, Australia, March 2020 The Australian Government is simplifying the clinical eligibility criteria for the Continuous Glucose Monitoring (CGM) Initiative from the 1st of March, 2020. This will allow people with type 1 diabetes under the age of 21, and those over the age of 21 who have valid concessional status to access fully subsidised CGM …

Continue reading "The Australian Government Simplifies the Clinical Eligibility Criteria for the Continuous Glucose Monitoring (CGM) Initiative"

Sydney, Australia, May 2019 AMSL Diabetes are excited to announce that they have signed a distribution agreement with MannKind Corporation (NASDAQ: MNKD) to introduce their patient-focused therapies to the Australian market. The exclusive partnership is set to benefit Australian diabetes patients by offering a new innovative technology solution for their diabetes management. “We are excited …

Continue reading "AMSL Diabetes Partner with MannKind Corporation"

Sydney, Australia, November 2018 Inclusion of LifeScan OneTouch Blood Glucose Test Strips on the NDSS Product Schedule.                                                                   The Australian Government recently undertook a …

Continue reading "NDSS Blood Glucose Strips Review Press Release"

Sydney, Australia, August 2018 AMSL Diabetes are delighted to announce they have partnered with Tandem Diabetes Care®, Inc. AMSL Diabetes have partnered with Tandem Diabetes Care, to introduce their innovative product range to the Australian market for the very first time. The exclusive partnership is set to benefit Australian type 1 diabetes patients by offering …

Continue reading "Tandem Diabetes Care Partnership Announcement"